| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10901905 | Cancer Letters | 2015 | 22 Pages |
Abstract
Metformin and EGFR-TKI have a synergistic effect in the treatment of DM2 NSCLC patients harboring EGFR-activating mutations. Metformin use is associated with improved survival and delayed onset of acquired resistance to EGFR-TKI.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Hengyi Chen, Wenxiu Yao, Qian Chu, Rui Han, Yubo Wang, Jianguo Sun, Dong Wang, Yongsheng Wang, Mengshu Cao, Yong He,